IGX Logo Medium Size.jpg
IntelGenx Reports Third Quarter 2018 Financial Results
08 nov. 2018 16h00 HE | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 08, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today reported financial results for the third quarter...
IGX Logo Medium Size.jpg
The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®
31 oct. 2018 08h00 HE | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 31, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for...
IGX Logo Medium Size.jpg
IntelGenx Announces Successful Results from RIZAPORT® Bioequivalence Study
24 sept. 2018 08h00 HE | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced successful results from a bioequivalence study for...
IGX Logo Medium Size.jpg
IntelGenx Reports Second Quarter 2018 Financial Results
09 août 2018 16h17 HE | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 09, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the second quarter...
IGX Logo Medium Size.jpg
IntelGenx Announces Notice of Grant of European Patent Covering  Rizaport® VersaFilm™
19 juin 2018 08h00 HE | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, June 19, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that the European Patent Office (“EPO”) has issued a...
red.jpg
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
13 févr. 2015 10h18 HE | RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...